3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer

A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00300508

Enrollment

856

Registered

2006-03-09

Start date

1996-01-31

Completion date

Unknown

Last updated

2009-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Hormone receptor positive breast cancer

Brief summary

The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.

Interventions

DRUGAnastrozole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 80 Years

Healthy volunteers

Inclusion criteria

* No disease recurrence at time of randomization, * patients with breast cancer after surgery, * 5 years (+/- 12 months) of prior endocrine therapy

Exclusion criteria

* Premenopausal patients, * unknown or negative receptor status, * Secondary malignant tumor

Design outcomes

Primary

Measure	Time frame
Recurrence-free and overall survival	—

Secondary

Measure	Time frame
Secondary cancers	—

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026